Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).

NCT01830478 is registered in ClinicalTrials.gov with Gruppo Italiano Studio Linfomi as lead sponsor.

NCT NCT01830478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01830478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).
Lead sponsor
Gruppo Italiano Studio Linfomi
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2009
Completion date
October 31, 2014
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non hodgkin lymphoma